Oregon Health & Science University

Oregon Health & Science University, a state-controlled academic medical center and research institution headquartered in Portland, Oregon, operates as a prime recipient on federal research grants and a prime contractor on clinical service delivery contracts with the Department of Veterans Affairs, National Institutes of Health, and other civilian agencies. OHSU does not compete under small-business set-asides and operates exclusively in full-and-open federal procurements, with 88% of recent awards held as prime positions across contracts and grants.

OHSU's federal footprint divides into two distinct streams: a substantial clinical-services segment anchored to the Veterans Health Administration through indefinite delivery contracts for specialized physician services, reference laboratory testing, transplant surgery, and biostatistical support; and a research-grant portfolio concentrated in the National Institutes of Health, where the institution holds direct funding from the National Cancer Institute, National Institute of Child Health and Human Development, National Institute of Allergy and Infectious Diseases, and other NIH institutes. Recent clinical work includes a $997,971.83 delivery order from Veterans Integrated Service Network 20 for interventional radiology physician services (awarded October 2026, through September 2027), a $2.07 million delivery order for reference laboratory testing (April 2026, through March 2027), and a $5.76 million delivery order for deceased donor organ procurement services including kidneys and livers (March 2026, through February 2027). OHSU holds multiple indefinite delivery contracts with VISN 20, including single-award IDIQs for biostatistical research services ($750,000 ceiling, September 2026–September 2030) and public health approaches to firearm injury prevention ($1,000,000 ceiling, September 2026–September 2031), both issued as sole-source under 38 U.S.C. 8153 for VA academic affiliates.

Customer concentration is split between research and clinical revenue streams. VISN 20 ranks first by award count across the recent portfolio (577 awards, $377.7 million combined potential value) and second by dollar value, reflecting the intensity of clinical service delivery to the Portland VA Medical Center, a VHA Level 1A facility. The National Cancer Institute leads by potential value (239 awards, $500.4 million), followed by VISN 20, the Agency for Healthcare Research and Quality (102 awards, $108.3 million), the National Institute of Child Health and Human Development (174 awards, $49.8 million), and the National Institute of Allergy and Infectious Diseases (224 awards, $35.1 million). The recent portfolio comprises 5,723 awards with combined potential value of $1.24 billion, though combined obligated dollars of $8.46 billion (681% of potential value) signal substantial recompete and option-year activity. The portfolio encompasses 154 distinct federal customer agencies.

Federal grant work reflects OHSU's research mission across neuroscience, cancer biology, immunology, infectious disease, maternal-fetal health, and health services research. Representative recent awards include $3.401 billion from the National Institute on Aging for ferroptosis in oligodendrocytes and vascular endothelial cells in vascular cognitive impairment (August 2026, through July 2030); $1.398 million from the National Institute on Drug Abuse as a cooperative agreement to establish and operate the Safety and Clinical Outcomes of Psychedelic Use (SCOPE) Center, a national research resource (September 2026, through August 2028); $2.737 million from the National Human Genome Research Institute for high-throughput single-cell multiomic technologies for DNA methylation analysis (September 2026, through August 2030); $1.570 billion from the National Institute of Diabetes and Digestive and Kidney Diseases for AAV vector-mediated gene therapy for cystinuria type B (June 2026, through March 2030); and $799,752 from NIDDK for AAV vector-mediated gene therapy for Alport syndrome (September 2026, through May 2031). Grant recipients include the National Institute of Dental and Craniofacial Research, National Institute of Neurological Disorders and Stroke, National Eye Institute, National Heart Lung and Blood Institute, Bureau of Health Professionals, the Defense Health Agency, and the National Institute for Occupational Safety and Health.

Activity has grown modestly year over year—267 awards in 2023, 379 in 2024, 331 in 2025, and 227 in 2026—with 373 awards (combined potential value $36.8 million) reaching ultimate completion within the next twenty-four months and therefore exposed to recompete. Service Contract Inventory data show SCI-reportable invoiced revenue of $37 million across FY2022–FY2025 (FY2024 peak at $9 million), with 20.4 to 38.5 FTEs deployed annually on reportable federal service contracts. Median government-paid hourly rates across SCI prime contracts run around $120.99/hr, with rates ranging from $24.05/hr for support labor to $456.77/hr for specialized physician and senior research personnel. Across SCI-reportable prime contracts, subcontracting represents approximately 5% of total contractor hours, with 46 named subcontractors identified.

OHSU subcontracts to major research universities and health centers on grant work, including Johns Hopkins University, University of Washington, University of Pittsburgh, Vanderbilt University Medical Center, Stanford, Duke University, and others. As a sub-recipient, OHSU typically provides specialized clinical or research services—biostatistical analysis, immunological assays, primary care site administration, data management, neuroimaging acquisition—rather than full project leadership. OHSU also receives sub-awards from Auburn University (SERDP environmental remediation work), GE Medical Systems Information Technologies (AI algorithm development for trauma assessment), and Seattle Children's Hospital (TB vaccine immune response studies).

OHSU competes entirely in full-and-open procurements and does not hold SBA set-aside certifications. The institution's federal footprint is stratified by capability: clinical services through VA indefinite delivery contracts delivering physician specialty care, laboratory services, and organ procurement; basic and translational biomedical research through NIH grants spanning neuroscience, cancer, cardiovascular disease, infectious disease, and women's and children's health; and health services research through AHRQ and other agencies. Work is performed at Portland, Oregon 97239 and subordinate facilities including the Oregon National Primate Research Center, Casey Eye Institute, Knight Cancer Institute, and multiple OHSU schools and research centers.